DarioHealth Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by DarioHealth Corp. (NASDAQ: DRIO) on April 10, 2026. The report discloses a corporate governance event: the appointment of a new member to the Board of Directors.
Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on a personnel appointment and does not contain financial statements or performance data.
Material Changes
The material change reported is the addition of John R. Palumbo to the Board of Directors, effective immediately on April 10, 2026. Mr. Palumbo brings over 40 years of healthcare operating experience, including roles in early-stage ventures, Fortune 100 enterprises, and service on the boards of PM Pediatrics Management Group, Lucid Diagnostics, ivWatch, and QLess.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies related to the appointment were disclosed beyond standard regulatory statements. Mr. Palumbo will receive the same fees as other non-executive directors, with no special compensatory arrangements or conflicts of interest requiring disclosure under Item 404(a) of Regulation S-K.
Key Facts for Investor Verification
- New Director: John R. Palumbo was appointed to the Board of Directors on April 10, 2026.
- Experience: Mr. Palumbo has extensive healthcare leadership experience and currently serves on multiple healthcare and technology boards.
- Compensation: He will be compensated at the standard rate for non-executive directors.
- Financial Data: No financial results or metrics are included in this specific filing.